{{Refimprove|date=June 2017}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457119778
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = 
| target            = [[interleukin 22|IL-22]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1007106-86-6
| ATC_prefix        = none
| ATC_suffix        = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0S77U25XZ3
| PubChem           = 
| KEGG = D09615
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| C=6408 | H=9873 | N=1706 | O=2016 | S=44
| molecular_weight = 143.87 kg/mol
}}

'''Fezakinumab''' is a human monoclonal antibody against [[interleukin-22]],<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fezakinumab.pdf|accessdate=2017-06-07}}</ref> designed for the treatment of [[psoriasis]] and [[rheumatoid arthritis]].<ref>{{cite web |url=http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf |title=Archived copy |accessdate=2012-09-25 |deadurl=yes |archiveurl=https://web.archive.org/web/20110904221453/http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf |archivedate=2011-09-04 |df= }} </ref> 

[[Wyeth]] discovered and initially developed the drug, and clinical development continued after that company was acquired by [[Pfizer]].  Fezakinumab, in combination with [[methotrexate]], completed a phase II trial in rheumatoid arthritis,<ref>{{cite web|url=http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4 |title=Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis|page=4|website=Lmt.projectsinknowledge.com |date= |accessdate=2017-06-07}}</ref> but data was not released. Development was discontinued in August 2011.

== References ==
<references/>

{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Wyeth]]
[[Category:Abandoned drugs]]

javascript:void(0);
{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}